{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12504.705","value":"10766.23"},{"groupId":"OG001","spread":"53873.432","value":"88900.26"},{"groupId":"OG002","spread":"99806.129","value":"165035.89"},{"groupId":"OG003","spread":"116322.7494","value":"185,532.5800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).","dispersionType":"Standard Deviation","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion (1.2-10x10\\^9 transduced cells).","id":"OG003","title":"Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"MEAN","populationDescription":"Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel and had a post-infusion sample tested for persistence","reportingStatus":"POSTED","timeFrame":"From afamitresgene autoleucel infusion up to 18 months post-infusion","title":"Peak Persistence","type":"PRIMARY","unitOfMeasure":"DNA copies/microgram"}